metformin has been researched along with B16 Melanoma in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin was administered before and during the induction of resistance to DTIC (MET-DTIC)." | 1.72 | Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance. ( Cecchini, AL; Cecchini, R; da Silva Brito, WA; Lopes, NMD; Luiz, RC; Marinello, PC; Sanches, LJ, 2022) |
| "Metformin has been reported to possess antitumor activity and maintain high cytotoxic T lymphocyte (CTL) immune surveillance." | 1.48 | Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. ( Cai, S; Cha, JH; Chan, LC; Chang, SS; Chang, WC; Chen, CH; Hadad, S; Hsu, JL; Hung, MC; Khoo, KH; Kim, T; Kuo, CW; Lee, HH; Li, CW; Lim, SO; Litton, JK; McCoy, AM; Mittendorf, EA; Moulder, SL; Piwnica-Worms, H; Purdie, CA; Symmans, WF; Thompson, AM; Tu, Y; Wang, HL; Wei, Y; Xia, W; Yang, WH, 2018) |
| "Metastasis is the main problem in successful treatment of many types of cancer such as melanoma." | 1.46 | Preparation and characterization of metformin surface modified cellulose nanofiber gel and evaluation of its anti-metastatic potentials. ( Akbari, V; Nurani, M; Taheri, A, 2017) |
| "Treatment with metformin began on day 3 and on day 14, the mice were killed." | 1.46 | Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma. ( Bernardes, SS; Cecchini, AL; Cecchini, R; de Souza Neto, FP; Luiz, RC; Marinello, PC; Melo, GP, 2017) |
| "Melanoma is a largely incurable skin malignancy owing to the underlying molecular and metabolic heterogeneity confounded by the development of resistance." | 1.42 | Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. ( Bhat, MK; Chaube, B; Malvi, P; Meena, AS; Mohammad, N; Singh, SV, 2015) |
| "Treatment with metformin did not stimulate expression of the cycle blocker p21, indicating that p21 was dispensable for the observed cell cycle arrest." | 1.37 | In vitro and in vivo anti-melanoma action of metformin. ( Harhaji-Trajkovic, L; Janjetovic, K; Micic, D; Misirkic-Marjanovic, M; Stevanovic, D; Sumarac-Dumanovic, M; Trajkovic, V; Vucicevic, L; Zogovic, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sanches, LJ | 1 |
| Marinello, PC | 2 |
| da Silva Brito, WA | 1 |
| Lopes, NMD | 1 |
| Luiz, RC | 2 |
| Cecchini, R | 2 |
| Cecchini, AL | 2 |
| Nojima, I | 1 |
| Eikawa, S | 1 |
| Tomonobu, N | 1 |
| Hada, Y | 1 |
| Kajitani, N | 1 |
| Teshigawara, S | 1 |
| Miyamoto, S | 1 |
| Tone, A | 1 |
| Uchida, HA | 1 |
| Nakatsuka, A | 1 |
| Eguchi, J | 1 |
| Shikata, K | 1 |
| Udono, H | 1 |
| Wada, J | 1 |
| Xu, A | 1 |
| Lee, J | 1 |
| Zhao, Y | 1 |
| Wang, Y | 1 |
| Li, X | 1 |
| Xu, P | 1 |
| Nurani, M | 1 |
| Akbari, V | 1 |
| Taheri, A | 1 |
| Limagne, E | 1 |
| Thibaudin, M | 1 |
| Euvrard, R | 1 |
| Berger, H | 1 |
| Chalons, P | 1 |
| Végan, F | 1 |
| Humblin, E | 1 |
| Boidot, R | 1 |
| Rébé, C | 1 |
| Derangère, V | 1 |
| Ladoire, S | 1 |
| Apetoh, L | 1 |
| Delmas, D | 1 |
| Ghiringhelli, F | 1 |
| de Souza Neto, FP | 1 |
| Bernardes, SS | 1 |
| Melo, GP | 1 |
| Cha, JH | 1 |
| Yang, WH | 1 |
| Xia, W | 1 |
| Wei, Y | 1 |
| Chan, LC | 1 |
| Lim, SO | 1 |
| Li, CW | 1 |
| Kim, T | 1 |
| Chang, SS | 1 |
| Lee, HH | 1 |
| Hsu, JL | 1 |
| Wang, HL | 1 |
| Kuo, CW | 1 |
| Chang, WC | 1 |
| Hadad, S | 1 |
| Purdie, CA | 1 |
| McCoy, AM | 1 |
| Cai, S | 1 |
| Tu, Y | 1 |
| Litton, JK | 1 |
| Mittendorf, EA | 1 |
| Moulder, SL | 1 |
| Symmans, WF | 1 |
| Thompson, AM | 1 |
| Piwnica-Worms, H | 1 |
| Chen, CH | 1 |
| Khoo, KH | 1 |
| Hung, MC | 1 |
| Yu, X | 1 |
| Zhou, W | 1 |
| Wang, H | 1 |
| Lu, S | 1 |
| Jin, Y | 1 |
| Fu, J | 1 |
| Chaube, B | 1 |
| Malvi, P | 1 |
| Singh, SV | 1 |
| Mohammad, N | 1 |
| Meena, AS | 1 |
| Bhat, MK | 1 |
| Scharping, NE | 1 |
| Menk, AV | 1 |
| Whetstone, RD | 1 |
| Zeng, X | 1 |
| Delgoffe, GM | 1 |
| Janjetovic, K | 1 |
| Harhaji-Trajkovic, L | 1 |
| Misirkic-Marjanovic, M | 1 |
| Vucicevic, L | 1 |
| Stevanovic, D | 1 |
| Zogovic, N | 1 |
| Sumarac-Dumanovic, M | 1 |
| Micic, D | 1 |
| Trajkovic, V | 1 |
| Lee, JS | 1 |
| Kim, WS | 1 |
| Kim, JJ | 1 |
| Chin, YW | 1 |
| Jeong, HC | 1 |
| Choi, JS | 1 |
| Min, HG | 1 |
| Cha, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Neoadjuvant Transcatheter Arterial Chemoembolization（TACE）Plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma[NCT04799548] | Phase 2 | 71 participants (Anticipated) | Interventional | 2021-12-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for metformin and B16 Melanoma
| Article | Year |
|---|---|
Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Cell Line, Tu | 2022 |
Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis.
Topics: Animals; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Experimental; Diet, High-Fat; Female; Lympho | 2020 |
Potential effect of EGCG on the anti-tumor efficacy of metformin in melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Nucleus; | 2021 |
Preparation and characterization of metformin surface modified cellulose nanofiber gel and evaluation of its anti-metastatic potentials.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cellulose; Gels; Melanoma, Experime | 2017 |
Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.
Topics: Acetylation; Animals; Carbazoles; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Line, Tumor | 2017 |
Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
Topics: Animals; Cell Proliferation; Humans; Hypoglycemic Agents; Melanoma, Experimental; Metformin; Mice; M | 2017 |
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; CTLA | 2018 |
Transdermal metformin hydrochloride-loaded cubic phases: in silico formulation optimization, preparation, properties, and application for local treatment of melanoma.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Hypoglyce | 2019 |
Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Lin | 2015 |
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia.
Topics: Animals; Antineoplastic Agents, Immunological; Cytokines; Cytotoxicity, Immunologic; Drug Synergism; | 2017 |
In vitro and in vivo anti-melanoma action of metformin.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; bcl-2-Associate | 2011 |
Identification of anti-melanogenic natural compounds from Galega officinalis and further drug repositioning.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Dose-Response Rela | 2012 |